Literature DB >> 21421461

Treatment recommendations for metastatic colorectal cancer.

Enrique Aranda1, Albert Abad, Alfredo Carrato, Andrés Cervantes, Jesús García-Foncillas, Pilar García Alfonso, Rocío García Carbonero, Auxiliadora Gómez España, Josep M Tabernero, Eduardo Díaz-Rubio.   

Abstract

Metastatic colorectal cancer (CRC) represents an important health problem in which several biological predictive and prognostic factors have been identified, including clinical features and molecular markers that might influence the response to treatment. Actually, certain prognostic factors are considered key elements, along with disease extent, for deciding the therapeutic approach. However, a distinction between resectable/potentially resectable and unresectable patients must be made in order to establish an adequate therapeutic strategy. Different drugs and chemotherapy regimens are currently available, and their administration depends on patient characteristics, disease-related factors and the treatment objective. Moreover, special situations such as peritoneal carcinomatosis and local treatment of CRC in the setting of metastatic disease should be considered when deciding the most appropriate treatment strategy. This article reviews all the previously mentioned issues involved in the management of metastatic CRC and suggests some general recommendations for its treatment.

Entities:  

Mesh:

Year:  2011        PMID: 21421461     DOI: 10.1007/s12094-011-0636-7

Source DB:  PubMed          Journal:  Clin Transl Oncol        ISSN: 1699-048X            Impact factor:   3.405


  178 in total

1.  Follow-up of patients treated by cytoreduction and chemotherapy for peritoneal carcinomatosis of colorectal origin.

Authors:  V J Verwaal; F A N Zoetmulder
Journal:  Eur J Surg Oncol       Date:  2004-04       Impact factor: 4.424

Review 2.  Liver resection for metastatic colorectal cancer in the age of neoadjuvant chemotherapy and bevacizumab.

Authors:  Peter S Yoo; Reynold I Lopez-Soler; Walter E Longo; Charles H Cha
Journal:  Clin Colorectal Cancer       Date:  2006-09       Impact factor: 4.481

3.  Tumor progression while on chemotherapy: a contraindication to liver resection for multiple colorectal metastases?

Authors:  René Adam; Gerard Pascal; Denis Castaing; Daniel Azoulay; Valerie Delvart; Bernard Paule; Francis Levi; Henri Bismuth
Journal:  Ann Surg       Date:  2004-12       Impact factor: 12.969

4.  Phase II trial of infusional fluorouracil, irinotecan, and bevacizumab for metastatic colorectal cancer: efficacy and circulating angiogenic biomarkers associated with therapeutic resistance.

Authors:  Scott Kopetz; Paulo M Hoff; Jeffrey S Morris; Robert A Wolff; Cathy Eng; Katrina Y Glover; Rosie Adinin; Michael J Overman; Vincete Valero; Sijin Wen; Christopher Lieu; Shaoyu Yan; Hai T Tran; Lee M Ellis; James L Abbruzzese; John V Heymach
Journal:  J Clin Oncol       Date:  2009-12-14       Impact factor: 44.544

5.  Recurrences after peritoneal carcinomatosis of colorectal origin treated by cytoreduction and hyperthermic intraperitoneal chemotherapy: location, treatment, and outcome.

Authors:  Vic J Verwaal; Henk Boot; Berthe M P Aleman; Harm van Tinteren; Frans A N Zoetmulder
Journal:  Ann Surg Oncol       Date:  2004-03-15       Impact factor: 5.344

6.  Circulating tumor cells in colorectal cancer: correlation with clinical and pathological variables.

Authors:  J Sastre; M L Maestro; J Puente; S Veganzones; R Alfonso; S Rafael; J A García-Saenz; M Vidaurreta; M Martín; M Arroyo; M T Sanz-Casla; E Díaz-Rubio
Journal:  Ann Oncol       Date:  2008-01-22       Impact factor: 32.976

7.  The management of synchronous peritoneal carcinomatosis and hematogenous metastasis from colorectal cancer.

Authors:  C P Carmignani; G Ortega-Perez; P H Sugarbaker
Journal:  Eur J Surg Oncol       Date:  2004-05       Impact factor: 4.424

8.  Failure analysis of recurrent disease following complete cytoreduction and perioperative intraperitoneal chemotherapy in patients with peritoneal carcinomatosis from colorectal cancer.

Authors:  Lana Bijelic; Tristan D Yan; Paul H Sugarbaker
Journal:  Ann Surg Oncol       Date:  2007-05-15       Impact factor: 5.344

9.  Predicting the survival of patients with peritoneal carcinomatosis of colorectal origin treated by aggressive cytoreduction and hyperthermic intraperitoneal chemotherapy.

Authors:  V J Verwaal; H van Tinteren; S van Ruth; F A N Zoetmulder
Journal:  Br J Surg       Date:  2004-06       Impact factor: 6.939

10.  Different strategies of sequential and combination chemotherapy for patients with poor prognosis advanced colorectal cancer (MRC FOCUS): a randomised controlled trial.

Authors:  Matthew T Seymour; Timothy S Maughan; Jonathan A Ledermann; Clare Topham; Roger James; Stephen J Gwyther; David B Smith; Stephen Shepherd; Anthony Maraveyas; David R Ferry; Angela M Meade; Lindsay Thompson; Gareth O Griffiths; Mahesh Kb Parmar; Richard J Stephens
Journal:  Lancet       Date:  2007-07-14       Impact factor: 79.321

View more
  10 in total

Review 1.  Role of stereotactic body radiotherapy for oligometastasis from colorectal cancer.

Authors:  Atsuya Takeda; Naoko Sanuki; Etsuo Kunieda
Journal:  World J Gastroenterol       Date:  2014-04-21       Impact factor: 5.742

2.  Effect of primary tumor location and tumor size on the response to radiotherapy for liver metastases from colorectal cancer.

Authors:  Hiroshi Doi; Kenji Uemoto; Osamu Suzuki; Koichi Yamada; Norihisa Masai; Daisaku Tatsumi; Hiroya Shiomi; Ryoong-Jin Oh
Journal:  Oncol Lett       Date:  2017-05-12       Impact factor: 2.967

Review 3.  Cytoreductive surgery and intraperitoneal chemotherapy for treatment of peritoneal carcinomatosis from colorectal origin.

Authors:  F Losa; P Barrios; R Salazar; J Torres-Melero; M Benavides; T Massuti; I Ramos; E Aranda
Journal:  Clin Transl Oncol       Date:  2013-06-06       Impact factor: 3.405

4.  Clinical stages of colorectal cancer diagnosed in obese and overweight individuals in the Polish Colonoscopy Screening Program.

Authors:  Piotr Spychalski; Jarek Kobiela; Paulina Wieszczy; Michał F Kamiński; Jarosław Reguła
Journal:  United European Gastroenterol J       Date:  2019-03-21       Impact factor: 4.623

5.  PDGFRα/β and VEGFR2 polymorphisms in colorectal cancer: incidence and implications in clinical outcome.

Authors:  Purificacion Estevez-Garcia; Angel Castaño; Ana C Martin; Fernando Lopez-Rios; Joaquin Iglesias; Sandra Muñoz-Galván; Iker Lopez-Calderero; Sonia Molina-Pinelo; Maria D Pastor; Amancio Carnero; Luis Paz-Ares; Rocio Garcia-Carbonero
Journal:  BMC Cancer       Date:  2012-11-12       Impact factor: 4.430

6.  Gene expression profile predictive of response to chemotherapy in metastatic colorectal cancer.

Authors:  Purificacion Estevez-Garcia; Fernando Rivera; Sonia Molina-Pinelo; Marta Benavent; Javier Gómez; Maria Luisa Limón; Maria Dolores Pastor; Julia Martinez-Perez; Luis Paz-Ares; Amancio Carnero; Rocio Garcia-Carbonero
Journal:  Oncotarget       Date:  2015-03-20

7.  Stereotactic body radiotherapy for patients with oligometastases from colorectal cancer: risk-adapted dose prescription with a maximum dose of 83-100 Gy in five fractions.

Authors:  Atsuya Takeda; Naoko Sanuki; Yuichiro Tsurugai; Yohei Oku; Yousuke Aoki
Journal:  J Radiat Res       Date:  2016-03-16       Impact factor: 2.724

8.  Prognostic Factors and Optimal Response Interval for Stereotactic Body Radiotherapy in Patients With Lung Oligometastases or Oligoprogression From Colorectal Cancer.

Authors:  Shuai Li; Dezuo Dong; Jianhao Geng; Xianggao Zhu; Chen Shi; Yangzi Zhang; Hongzhi Wang; Shun Zhou; Hao Wu; Yong Cai; Yongheng Li; Weihu Wang
Journal:  Front Oncol       Date:  2019-10-15       Impact factor: 6.244

9.  Treatment outcomes of stereotactic ablative body radiotherapy on oligometastases from colorectal cancer: early results of a single institution service evaluation.

Authors:  Julie Duong; Adele Stewart-Lord; Prasana Nariyangadu; Mark Harrison; Yat Man Tsang
Journal:  BJR Open       Date:  2022-03-11

10.  MiR-107 and miR-99a-3p predict chemotherapy response in patients with advanced colorectal cancer.

Authors:  Sonia Molina-Pinelo; Amancio Carnero; Fernando Rivera; Purificacion Estevez-Garcia; Juan Manuel Bozada; Maria Luisa Limon; Marta Benavent; Javier Gomez; Maria Dolores Pastor; Manuel Chaves; Rocio Suarez; Luis Paz-Ares; Fernando de la Portilla; Andres Carranza-Carranza; Isabel Sevilla; Luis Vicioso; Rocio Garcia-Carbonero
Journal:  BMC Cancer       Date:  2014-09-07       Impact factor: 4.430

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.